Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
DVAX Stock Chart & Stats
$10.80
-$0.11(-0.86%)
At close: 4:00 PM EST
$10.80
-$0.11(-0.86%)
Day’s Range― - ―
52-Week Range$9.20 - $14.63
Previous CloseN/A
Volume272.71K
Average Volume (3M)1.59M
Market Cap
$1.30B
Enterprise Value$996.54M
Total Cash (Recent Filing)$647.82M
Total Debt (Recent Filing)$285.02M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Feb 19, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding117,424,965
10 Day Avg. Volume2,046,469
30 Day Avg. Volume1,585,088
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.78
Price to Sales (P/S)5.99
P/FCF Ratio27.60
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda-38.85
Forecast
1Y Price Target
$24.33Price Target Upside125.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Share GrowthDynavax's market share in the U.S. HBV market increased to 46%, showing growth and strong market presence.
Retail Segment DemandRetail pharmacies have increased their prioritization of Heplisav, leading to a 63% share of the retail segment, suggesting strong demand.
Strategic InvestmentThe potential for Dynavax to opt into further development of Vaxart's oral COVID-19 vaccine candidate depends on positive Phase IIb data, indicating a strategic approach to investment.
Bears Say
Financial RisksDynavax's licensing agreement with Vaxart involves significant financial commitments and future payments, bringing potential financial risk if the vaccine candidate does not meet expectations.
Sales PerformanceThird-quarter Heplisav sales of $90 million came slightly below estimates and consensus, attributed to a later start of the flu vaccination season.
Dynavax News
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.20 and its highest was $14.63 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.30B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Feb 19, 2026 which is in 89 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Oct 24, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.126 by $0.084.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.05.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 117,424,965 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.21 in its last earnings report, beating expectations of $0.126. Following the earnings report the stock price went up 1.06%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
Dynavax Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.33 (125.28% Upside)
$24.33 (125.28% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.25%
12-Months-Change
Fundamentals
Return on Equity
-7.14%
Trailing 12-Months
Asset Growth
-10.87%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corporation (DVAX) is a biopharmaceutical company focused on developing and commercializing novel vaccines and therapeutics. The company primarily operates in the biotechnology sector, with a strong emphasis on immunology and infectious diseases. Its core product is HEPLISAV-B, a hepatitis B vaccine that is unique in its formulation, which provides a faster and more effective immune response compared to traditional vaccines. Dynavax is also involved in the development of other immunotherapies and vaccines, leveraging its proprietary technology platforms.
DVAX Company Deck
DVAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic advancements in the company's pipeline and partnerships, notably with Vaxart. Despite a few concerns about potential seasonal impacts and a decrease in cash reserves, the company's overall financial health and strategic initiatives suggest a positive outlook.View all DVAX earnings summariesDVAX Stock 12 Month Forecast
Average Price Target
$24.33
▲(125.28% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
13.92% Insiders
15.53% Mutual Funds
27.62% Other Institutional Investors
20.17% Public Companies and
Individual Investors